Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05OFX
|
|||
| Former ID |
DCL000858
|
|||
| Drug Name |
Lacosamide
|
|||
| Synonyms |
Erlosamide; Harkoseride; Vimpat; Erlosamide [INN]; Lacosamide [USAN]; ADD 234037; SPM 927; ADD-234037; SPM-927; SPM-929; Erlosamide, Vimpat, Lacosamide; Lacosamide (USAN/INN); (2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide; (2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide; (2R)-2-acetamido-N-benzyl-3-methoxypropanamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Convulsion [ICD-11: 8A68.Z; ICD-9: 780.3] | Approved | [1], [2] | |
| Epilepsy [ICD-11: 8A60-8A68] | Approved | [3], [4] | ||
| Diabetic neuropathy [ICD-11: 8C0Z] | Phase 3 | [1], [5] | ||
| Therapeutic Class |
Analgesics
|
|||
| Company |
Schwarz Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H18N2O3
|
|||
| Canonical SMILES |
CC(=O)NC(COC)C(=O)NCC1=CC=CC=C1
|
|||
| InChI |
1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1
|
|||
| InChIKey |
VPPJLAIAVCUEMN-GFCCVEGCSA-N
|
|||
| CAS Number |
CAS 175481-36-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9374274, 12015335, 14847708, 15196715, 30422445, 50069298, 51091636, 53505872, 57399840, 58107206, 99218530, 99298399, 99437053, 103245465, 104154565, 109693474, 113468551, 123121578, 124757118, 125163922, 126575044, 126624062, 126644682, 126667072, 126733504, 129508865, 134339319, 135141960, 135367753, 135697647, 135707761, 136895303, 136991060, 137237313, 137237672, 139113413, 152258417, 160647253, 160660621, 160826045, 162037520, 162188094, 163092695, 163589394, 164824528, 170466190, 172086321, 174006177, 174527897, 175266112
|
|||
| ChEBI ID |
CHEBI:135939
|
|||
| ADReCS Drug ID | BADD_D01238 | |||
| SuperDrug ATC ID |
N03AX18
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dihydropyrimidinase related protein 2 (DPYSL2) | Target Info | Modulator | [2] |
| Voltage-gated sodium channel (Nav) | Target Info | Inhibitor | [3] | |
| Voltage-gated sodium channel alpha Nav1.9 (SCN11A) | Target Info | Inhibitor | [3] | |
| Reactome | Interaction between L1 and Ankyrins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7472). | |||
| REF 2 | 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. | |||
| REF 3 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.